세포탁심 나트륨
세포탁심나트륨 · 세포탁심나트륨(CEFOTAXIMESODIUM) · ctx · CEFOTAXIME SODIUM STERILE · CEFOTAXIME SODIUM SALT · CLAFORAN · Sodium cefotaxime · CEFOTAXIME NA-SALT
식별자 및 물리적 특성
| CAS No. | 64485-93-4 |
|---|---|
| 분자식 | C16H16N5NaO7S2 |
| 평균 분자량 | 477.5 g/mol |
| 단동위원소 질량 | 477.03888413 g/mol |
| SMILES | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(C)=O)CS[C@H]12)c1csc(N)n1.[Na+] |
| InChIKey | AZZMGZXNTDTSME-JUZDKLSSSA-M |
| PubChem CID | 10695961 |
| ChEMBL | CHEMBL1010 |
| ChEBI | CHEBI:3498 |
| EC No. | 264-915-9 |
| DTXSID | DTXSID4046991 |
| 현지명 | 세포탁심 나트륨 |
화학 및 물리적 성질
| 극성 표면적 | 230 |
|---|---|
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 12 |
| 회전 가능 결합 수 | 8 |
| 무거운 원자 수 | 31 |
| 형식 전하 | 0 |
| 복잡도 | 839 |
| 용해도 | 68.2 [ug/mL] (The mean of the results at pH 7.4)H2O: pH 4.3-6.2의 수용액은 2-8 ℃에서 최대 3주 동안 안정합니다. |
| Human Drugs | FDA approved drugs -> Active ingredient |
| 녹는점 | 162-163 C |
| 굴절률 | 61 ° (C=1, H2O) |
| 저장 조건 | Keep in dark place,Inert atmosphere,2-8°C |
| 물리적 상태 | 가루 |
| 색상 | 흰색에서 노란색으로 |
| pH | pH(100g/l, 25℃) : 4.5～6.5 |
| 용해도 | 물에 용해됩니다. |
| Merck | 14,1933 |
| BRN | 5711411 |
| 안정성 | 안정적인. 강한 산화제와 호환되지 않습니다. |
| InChIKey | ACGQSCNTUWPWNB-RRVHIMMXNA-N |
| SMILES | C(C1=C(CS[C@]2([H])[C@H](NC(=O)/C(/C3=CSC(N)=N3)=N\OC)C(=O)N12)COC(=O)C)(=O)O.[NaH] |&1:5,7,r| |
화학적 성질
White to pale yellow crystalline powder
안전 및 규제
| GHS 분류 | DangerH317 (99.2%): May cause an allergic skin reaction [Warning Sensitization, Skin]P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 132 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Cefotaxime sodium: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Skin Sens. 1 (99.2%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Cefotaxime sodiumvLess-DILI-concern5Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| 수질 위해 등급(WGK) | 2 |
| RTECS 번호 | XI0250000 |
| 관세 코드 | 29419000 |
| 위험 문구(R) | 42/43 |
| 위험 표시 | Xn,Xi |
| 안전 문구(S) | 22-36/37-60-45-37-24 |
| 위험 등급 | Resp. Sens. 1Skin Sens. 1 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
Cefotaxime was synthesized by Hoechst and Roussel-Uclaf in 1977. It was the first derivative of cephalosporin to introduce the methoxyimino and aminothiazole groups at the 7 position of the cephem nucleus. Although it shows unexpectedly low oral absorption, its excellent activity against a wide range of gram-positive and gram-negative organisms, including Serratia, Enterobacter, Citrobacter, and anaerobes, guided research and development of the newer synthetic cephems, the so-called thirdgeneration cephalosporins.
용도
Cefotaxime sodium salt acts as a beta-lactamase resistant antibiotic. It is used as an effective antibacterial against gram-negative bacteria, with the notable exception of pseudomonas and penicillin-resistant strains of streptococcus pneumoniae. It is used to treat infections of the bones, joints, skin, respiratory tract and blood stream.
일반 설명
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards